Dariohealth Corp. (DRIO) Stock Price & Analysis
Dariohealth Corp. (DRIO) rose 4.28% to USD 7.79 as of July 25, 2026 at 08:34 UTC, according to Nexqual real-time market data.
DRIO last closed at USD 7.47; the session ranged USD 7.79–7.81 on volume of 1,835 shares. Market capitalization is $56.96M, with a 52-week range of USD 5.85–17.74 (NCM). Source: Nexqual, July 25, 2026 at 08:34 UTC.
Key Statistics (as of July 25, 2026 at 08:34 UTC)
| Price | USD 7.79 |
|---|---|
| Change | ▲ 4.28% (up) |
| Previous Close | USD 7.47 |
| Open | USD 7.81 |
| Day Range | USD 7.79 – 7.81 |
| 52-Week Range | USD 5.85 – 17.74 |
| Volume | 1,835 shares |
| Market Cap | $56.96M |
| Exchange | NCM |
Technical Analysis (DRIO)
Nexqual's technical model rates DRIO "BUY" based on 5 bullish and 2 bearish signals across 125 daily candles, as of July 25, 2026 at 08:34 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 58.89 (neutral) |
| vs SMA50 | Above (USD 7.27) |
| MACD | 0.09 (positive) |
Analyst Ratings (DRIO)
Wall Street analysts rate DRIO "Strong Buy" based on 4 analysts, with a mean price target of USD 18.5 (range USD 10–28), per Nexqual as of July 25, 2026 at 08:34 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 18.5 |
| High Target | USD 28 |
| Low Target | USD 10 |
| Buy / Hold / Sell | 3 / 1 / 0 |
Earnings (DRIO)
| Next Earnings Date | 2026-08-11 |
|---|---|
| EPS Estimate | USD -0.76 |
| Revenue Estimate | $5.66M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.95 vs est -0.85 ▼ miss |
| 2025-12-31 | USD -0.77 vs est -1.59 ▲ beat |
| 2025-09-30 | USD -2.22 vs est -2.42 ▲ beat |
| 2025-06-30 | USD -4.09 vs est -2.07 ▼ miss |
Source: Nexqual, July 25, 2026 at 08:34 UTC.
Financials & Fundamentals (DRIO)
| Total Revenue | $21.19M |
|---|---|
| Revenue Growth (YoY) | -17.30% |
| Gross Margin | +61.13% |
| Operating Margin | -130.89% |
| Profit Margin | -192.23% |
| ROE | -59.87% |
| Debt / Equity | 51 |
| Current Ratio | 3.07 |
| Total Cash | $20.01M |
| Total Debt | $31.82M |
| Free Cash Flow | $-10.88M |
Source: Nexqual, July 25, 2026 at 08:34 UTC.
Financial Health Score (DRIO)
Nexqual rates Dariohealth Corp.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 08:34 UTC.
| Growth | Critical — Revenue -17% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $20M cash vs $32M debt |
| Cash Flow | Weak — FCF negative: -$11M, burning cash |
| Efficiency | Critical — ROE -60%, ROA -19.7% |
Ownership (DRIO)
| Insider Ownership | +15.74% |
|---|---|
| Institutional Ownership | +8.98% |
| Shares Outstanding | 7.31M |
| Float | 5.23M |
| Short % of Float | +1.07% |
Source: Nexqual, July 25, 2026 at 08:34 UTC.
Leadership (DRIO)
Dariohealth Corp. is led by Erez Raphael (age 52), CEO & Director, per Nexqual as of July 25, 2026 at 08:34 UTC.
| CEO & Director | Erez Raphael (age 52) |
|---|---|
| CFO, Treasurer & Secretary | Chen Franco-Yehuda (age 41) |
Major Backers & Investors (DRIO)
Notable institutional backers of Dariohealth Corp. include Nantahala Capital Management, LLC, Fidelity, Lasry, Marc, according to Nexqual as of July 25, 2026 at 08:34 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Nantahala Capital Management, LLC | 8.32% |
| Fidelity | 0.7% |
| Lasry, Marc | 0.32% |
| Citadel | 0.28% |
| UBS Group AG | 0.22% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 2.26% |
| Geode Capital | 0.84% |
| BlackRock | 0.26% |
| Northern Trust | 0.18% |
Source: Nexqual, July 25, 2026 at 08:34 UTC.
From Dariohealth Corp.'s Latest SEC 10-K Filing (filed 2026-03-19)
Key Strengths & Strategy (as disclosed to the SEC)
- DarioHealth Corp. operates as a digital health company in the United States and internationally.
- Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health.
- The company offers Dario Connect, a solution used to create communities around specific health conditions to increase awareness and education; Dario Mind, a behavioral health offering that decreases the symptoms of stress, anxiety, and depression; Dario Move, focuses on improving posture to alleviate pain with medical device; and Dario Health, a self-care application and virtual coaching platform for diabetes, hypertension, and weight management and GLP-1.
- It also provides bundled full-suite or partial-suite subscriptions.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PAVM | PAVmed Inc. | USD 4.74 | ▲ 0.42% |
| CLPT | ClearPoint Neuro Inc. | USD 14.12 | ▼ 6.05% |
| MYO | Myomo Inc. | USD 0.97 | ▼ 6.73% |
| CTSO | Cytosorbents Corporation | USD 0.36 | ▼ 5.76% |
| XBIO | Xenetic Biosciences, Inc. | USD 2.64 | ▼ 1.12% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 08:34 UTC. This page is informational and not investment advice.